Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance

Charles River Laboratories Intl. IncTrade
Vanguard High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Vanguard High Dividend Yield ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $285.14 (market cap $13.46B), while Vanguard High Dividend Yield ETF trades at $166.22. Which is the better fit depends on your goals.

CRLVYM
Market Cap
$13.46B
Sector
Health
52-Week High
$282.00$166.14
52-Week Low
$145.57$136.63
Enterprise Value
$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.

The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.

Vanguard High Dividend Yield ETF

VYM trades at $166.36, up 0.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on high dividend yield stocks, offering income appeal, though key valuation ratios like P/E and P/B are not available. Recent news highlights institutional position adjustments and discussions on its role in retirement income portfolios.

Outlook is mixed: technical indicators suggest near-term caution due to overbought conditions, while the dividend strategy supports long-term income. Risks include market volatility and yield compression. Analyst sentiment is generally positive for income-focused investors, but monitor for pullbacks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Vanguard High Dividend Yield ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VYM